The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The invention relates to a method for preparing a cellulose dope comprising mixing and dissolving the cellulosic raw material in dilute and concentrated aqueous organic solvent in a two-stage process to form a homogeneous slurry, followed by heating the homogeneous slurry to obtain a cellulose dope containing 11% to 20% cellulose by weight. The invention also relates to a cellulose dope comprising 11% to 20% cellulose by weight and 73% to 79% aqueous organic solvent wherein the concentration of the cellulosic and metallic impurities in the cellulose dope shows a percent reduction of 20% to 50% from the cellulosic raw material.

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin and methods for their use in treating disorders mediated by hemoglobin. (Formula (I))

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin and methods for their use in treating disorders mediated by hemoglobin. (Formula (I))

A composition includes a perfluorinated propenylamine represented by the following general formula (1):

Each occurrence of R.sub.f1 and R.sub.f2 is: (i) independently a linear or branched perfluoroalkyl group having 1-8 carbon atoms and optionally comprises one or more catenated heteroatoms; or (ii) bonded together to form a ring structure having 4-8 carbon atoms and that optionally comprises one or more catenated heteroatoms.

At least 60 wt. % of the perfluorinated propenylamine is in the form of the E isomer, based on the total weight of the perfluorinated propenylamine in the composition.

##STR00001##

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

Disclosed is an aromatic compound. Such compounds can locally produce a long-lasting nerve blocking effect, have an analgesic effect, an anti-pruritic effect, etc., and can be used in the preparation of a long-acting local anaesthetic drug, a local analgesic drug and an anti-pruritic drug.

The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.